Droxidopa (CAS 23651-95-8) Suppliers and Product Information

Droxidopa is a synthetic amino acid precursor of norepinephrine. It is used for treating neurogenic orthostatic hypotension and improves norepinephrine levels. Droxidopa crosses the blood-brain barrier and is converted to norepinephrine by DOPA decarboxylase. It has shown improvements in Parkinsonian patients when added to existing levodopa therapy, particularly for symptoms like retropulsion, dysarthria, and muscular rigidity.

Frequently Asked Questions about Droxidopa

Q: What is the main use of Droxidopa?

A: Droxidopa is primarily used for the treatment of neurogenic orthostatic hypotension, particularly in conditions like Parkinson's disease, multiple system atrophy, or pure autonomic failure. It helps alleviate symptoms such as dizziness and lightheadedness associated with blood pressure decline upon standing.

Q: How does Droxidopa work?

A: Droxidopa is a prodrug that is converted to norepinephrine in the body. It easily crosses the blood-brain barrier and is metabolized by DOPA-decarboxylase to increase norepinephrine levels, which helps regulate blood pressure and other autonomic functions.

Q: Are there any specific storage requirements for Droxidopa?

A: The predicted storage temperature for Droxidopa is -20°C. It is also noted to be hygroscopic, so it should be stored in a dry environment.

Q: Can Droxidopa be used in research applications?

A: Yes, Droxidopa is used in research, particularly in studies related to norepinephrine deficiency and amyloid pathology. It has shown potential in reducing amyloid plaques in animal studies.